Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/10/2017 |
| Start Date: | December 2002 |
An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
This research study was designed to determine the effectiveness of the drug, topotecan,
given intravenously (into a vein) together with the drug gemcitabine in patients with
recurrent platinum-sensitive ovarian, fallopian or primary peritoneal cancer, as well as
tumors of mixed mullerian origin. Additional purposes are to determine the long term outcome
and side effects of this combination treatment.
Since topotecan and gemcitabine have different mechanisms of action, the combination of
these 2 drugs may provide better results than either drug alone. Prior studies suggest that
the combination of topotecan and gemcitabine improves the effects on the tumor and also
appeared to be well tolerated.
given intravenously (into a vein) together with the drug gemcitabine in patients with
recurrent platinum-sensitive ovarian, fallopian or primary peritoneal cancer, as well as
tumors of mixed mullerian origin. Additional purposes are to determine the long term outcome
and side effects of this combination treatment.
Since topotecan and gemcitabine have different mechanisms of action, the combination of
these 2 drugs may provide better results than either drug alone. Prior studies suggest that
the combination of topotecan and gemcitabine improves the effects on the tumor and also
appeared to be well tolerated.
Inclusion Criteria:
- Have had one prior platinum-based chemotherapy regimen for the treatment of primary
disease.
- At least 4 weeks since last surgery or radiation therapy.
- Must have had a treatment-free interval of greater than 6 months following response
to platinum.
- ECOG performance status of 0,1, or 2.
Exclusion Criteria:
- Women of child-bearing potential that do not practice adequate contraception.
- Pregnant or lactating.
- Received more than one primary chemotherapy regimen.
- Concomitant or previous malignancies with the exception of adequately treated basal
cell or squamous cell skin cancer, in situ cervical cancer, incidental carcinoid, or
other cancer from which the patient has been disease free for 5 years.
- Active uncontrolled infection requiring antibiotics.
- Concurrent severe medical problems unrelated to the malignancy which would limit full
compliance with the study.
- Received radiation to more than 10% of bone.
- Prior treatment with topotecan or gemcitabine.
- Hypersensitivity to camptothecin or nucleoside analogues.
- Use of an investigational agent within 30 days.
We found this trial at
16
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials